In vivo immunomodulatory, cumulative skin irritation, sensitization and effect of d-limonene on permeation of 6-mercaptopurine through transdermal drug delivery

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 4, 2008, Pages 656-661

  Chandrashekar, N S ^a   Hiremath, Shobha Rani Rajeev ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

6 Mercaptopurine; D limonene; Immunomodulatory; Transdermal

Indexed keywords

ALPHA ESTERASE; ESTERASE; LIMONENE; MERCAPTOPURINE; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW CELL; CADAVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION; DRUG PENETRATION; DRUG STRUCTURE; FEMUR; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SKIN PENETRATION; SKIN SENSITIZATION;

6-MERCAPTOPURINE; ADMINISTRATION, CUTANEOUS; ANIMALS; BLOOD CELL COUNT; BONE MARROW CELLS; CELL MEMBRANE; CHEMISTRY, PHYSICAL; CYCLOHEXENES; DIFFUSION CHAMBERS, CULTURE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRRITANTS; MICE; MICE, INBRED BALB C; SKIN; SKIN ABSORPTION; TERPENES;

EID: 41849132168     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.656     Document Type: Article

References (32)

1. Prausnitz M. R., Mitragotri S., Langer R., Nat. Rev. Drug Discovery, 3, 115-124 (2004).
2. Finnin B. C., Morgan T. M., J. Pharm. Sci., 88, 955-958 (1999).
3. Henningfield J. E., N. Engl. J. Med., 333, 1196-1203 (1995).
4. Gupta P., Garg S., Pharm. Technol., 26, 144-161(2002).
5. Prausnitz M. R., Nat. Biotech., 24, 416-417 (2006).
6. Lim Chye P. F., Liu X. Y., Kang L., Paul Lui Ho P. C., Chan Y. W., Chan S. Y., Int. J. Pharm., 311, 157-164 (2006).
7. Barry B. W., Nat. Biotechnol., 22, 165-167 (2004).
8. Vyas S. P., Roop K. K., "Controlled Drug Delivery Concepts and Advances," Vallabh Prakashan, New Delhi, 2002.
9. Minghetti P., Cilurzo F., Tosi L., Asiraghi A., Montanari L., AAPS Pharm. Sci. Tech., 4, 1-8 (2003).
10. Kim J. H., Lee C. H., Choi H. K., Drug Dev. Ind. Pham., 28, 833-839 (2002).
11. Millard-Salin D. G., Becourt P., Couarraze G., Int. J. Pharm., 200, 121-126 (2000).
12. Dimas D. A., Dallas P. P., Rekkas D. M., Choulis N. H., AAPS Pharm. Sci. Tech., 1, 1-8 (2000)
13. Timmer A., McDonald J. W., Macdonald J. K., Cochrane Database Syst. Rev., 24, 478 (2007).
14. Nguyen G. C., Harris M. L., Dassopoulos T., Curr. Gastroenterol. Rep., 8, 499-450 (2006).
15. Shullenberger C. C., Cancer Chemother. Rep., 16, 251-252 (1962).
16. Sparrow M. P., Hande S. A., Friedman S., Cao D., Hanauer S. B., Clin. Gastroenterol. Hepatol., 5, 209-214 (2007).
17. Cuffari C., Hunt S., Bayless T. M., Alim. Pharmacol. Therap., 14, 1009-1014 (2000).
18. Romagnuolo J., Sadowski D. C., Lalor E., Jewell L., Thomson A. B., Can. J. Gastroenterol., 12, 479-483 (1988).
19. Murthy S. N., Shobha Rani R. H., AAPS PharmSciTech., 2, 1-5 (2001)
20. Kligman A. M., Christophers E., Arch. Dermatol., 88, 70-73 (1963).
21. Aqil M., Ali A., Sultana Y., Najmi A. K., Pharmazie, 59, 631-635 (2004).
22. Su M. H., Lee L. H., Addel G. H., Earl K. R., William H. I., Drug Dev. Ind. Pharm., 20, 685-718 (1994).
23. Moghimi H. R., Williams A. C., Barry B. W., Int. J. Pharm., 146, 41-54 (1997).
24. Zhao K., Singh J., J. Controlled Release, 55, 253-260 (1988).
25. Cornwell P. A., Barry B. W., Stoddart C. P., Bouwstra J. A., J. Pharm. Pharmcol., 46, 938-950 (1944).
26. Williams A. C., Barry B. W., Adv. Drug Deliv., 56, 603-618 (2004).
27. Hashida M., Yamashita F., "Percutaneous Penetration Enhancers," ed. by Smith E. W., Maibach H. I., CRC Press, Florida, 1995, pp. 309-321.
28. Krishnaiah Y. S. R., Satyanarayana V., Bhaskar P., Pharmazie, 57, 842-847 (2002).
29. Barry B. W., J. Controlled Release, 15, 237-248 (1991).
30. Ohara N., Takayama K., Machida Y., Nagai T., Int. J. Pharm., 105, 31-38 (1994).
31. Raphael T. J., Kuttan G., J. Exp. Clin. Cancer Res., 22, 419-424 (2003).
32. Crowell P. L., Gould M. N., Crit. Rev. Oncology, 5, 1-22 (1994).